Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ACDN-01-001: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Subretinal ACDN-01 in Participants With ABCA4-related Retinopathy

NCT06467344 is registered in ClinicalTrials.gov with Ascidian Therapeutics, Inc as lead sponsor.

NCT NCT06467344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06467344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ACDN-01-001: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Subretinal ACDN-01 in Participants With ABCA4-related Retinopathy
Lead sponsor
Ascidian Therapeutics, Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 11, 2024
Completion date
December 1, 2030
Enrollment
15 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cone rod dystrophy, juvenile macular degeneration, stargardt disease, stargardt disease 1